Renier J. Brentjens, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘06-‘11) and colleagues at the Memorial Sloan-Kettering Cancer Center, New York, reported the success of immunotherapy treatment of adults with acute lymphoblastic leukemia (ALL). Patients were treated with their own T immune cells, which had been genetically modified to target and attack the cancer cells. The treatment induced rapid remissions in these patients. The exciting findings were published in the journal Science Translational Medicine and featured in The New York Times and The Wall Street Journal.
